ARTICLE | Clinical News
CHMP recommends Ipsen's Xermelo for carcinoid syndrome diarrhea
July 28, 2017 4:27 PM UTC
EMA's CHMP recommended approval of Xermelo telotristat ethyl (LX1032, LX1606) from Ipsen Group (Euronext:IPN; Pink:IPSEY) to treat carcinoid syndrome diarrhea in combination with a somatostatin analog (SSA) inadequately controlled by SSA therapy...
BCIQ Target Profiles